DALLAS - CG Oncology reported on Nov.
367-Patient Trial Shows Clean Safety Profile
The study enrolled 367 patients across roughly 90 U.S. and Canadian sites, recording a 0.32 hazard ratio at a 17-month median follow-up as of Oct. 26.
No Grade 3 or higher treatment-related adverse events or treatment-related discontinuations occurred. 13, as the company noted about 50,000 U.S. patients in this group lack an FDA-approved post-surgery option.
Dual FDA Filings Targeted for 2027
Detailed topline findings will be presented at the Society of Urologic Oncology Annual Meeting on Dec. 2. CG Oncology also expects to finish a broadened initial FDA filing for BCG-unresponsive bladder cancer by the end of March 2027, with all supporting manufacturing steps completed.



